Nextrials and Allon Therapeutics Set New Benchmark for Releasing Clinical Trial Results

SAN RAMON, Calif.--(BUSINESS WIRE)--Jun 16, 2008 - Nextrials, Inc., a leader in clinical research software and services, today announced that its flagship Prism(R) clinical trial management software was used by Allon Therapeutics Inc. (TSX: NPC) to successfully manage and analyze results of a Phase IIa trial of a novel treatment for Alzheimer's disease. Using the Prism software, results from Allon's nine-month, 16-site clinical trial were announced in less than seven weeks after the final patient visit -- a notable achievement within the biopharmaceutical R&D community.

Karole Sutherland, Allon's vice president, clinical operations, said Prism enabled Allon to institute efficiencies that improved collaboration, substantiated the data quality and accelerated the review and announcement of the trial results. "This was the first proof of human efficacy for our compound -- and for an emerging company such as Allon Therapeutics, it was important to release high quality data as quickly as possible to our shareholders and to the investment and medical communities," said Sutherland.

Sutherland added that unique Prism features, such as the patient randomization module, real-time project alerts and nightly data extracts, allowed Allon to track trial progress and data integrity on an ongoing basis. "Since it was a blinded trial, we did not know the outcome until the trial was closed. However, the responsiveness of the Nextrials team and the efficiencies provided by Prism ensured that the data was clean immediately upon database lock," she said.

James Rogers, CEO and co-founder of Nextrials, said the company was able to work closely with Allon to close the study and lock the database in record time. "Seeing Allon successfully release its study results to the public in less than seven weeks after the final patient visit gives us additional proof that Prism can be a powerful ally in shortening the time to market for novel drugs and therapeutics," he said.

Attendees at the 44th Annual Meeting of the Drug Information Association, being held June 22-26 at the Boston (MA) Convention and Exhibition Center, can learn more about Nextrials' Prism by visiting Booth 1817.

About Allon Therapeutics Inc.

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. In Q1 2008, Allon's drug AL-108 demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease. Allon has Phase II human efficacy programs pursuing three large underserved markets: Alzheimer's disease, stroke and schizophrenia-related cognitive impairment. The company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company(TM)) and based in Vancouver. For additional information please visit the company's website: www.allontherapeutics.com.

About Nextrials, Inc.

Founded by pharmaceutical researchers in 1999, Nextrials Innovates for Life(TM) by offering today's most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism(R), its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000. A podcast by co-founder and CEO James Rogers on the incorporation of electronic health records into the clinical trial process is also available at http://pharmavoice.com/podcasts.

Contact

Nextrials, Inc.
James Rogers, 925-355-3000
jrogers@nextrials.com
or
VOXUS, Inc.
Rachel V. Berry, 253-853-5151, ext. 223
rberry@voxuspr.com

Posted: June 2008

View comments

Hide
(web2)